Surfactant Comes of Age

Jobe AH . Surfactant treatment for respiratory distress syndrome. Respir Care 1986;31:467–479.

Robillard E , Alarie Y , Dagenais-Peruse P. Microaerosol administration of synthetic beta-gamma-dipalmitoyl d-lecithin in the respiratory distress syndrome: A preliminary report. Can Med Assoc J 1964;90:55–57.

Morley CJ , Miller N , Bangham AD . Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981;1:64–68.

Milner A , Vyas H , Hopkin I. Effect of exogenous surfactant on total respiratory system compliance. Arch Dis Child 1984;59:369–371.

Van Golde LMG , Batenburg JJ , Robertson B. The pulmonary surfactant system: Biochemical aspects and functional significance. Physiol Rev 1988;68:374–455.

Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988.

Yerushalmy J. Classification of newborn infants by weight and gestational age. J Pediatr 1967;71:164–172.

King RJ . Isolation and chemical composition of pulmonary surfactant. In: Robertson B , Van Golde LMG , Batenburg JJ , eds. Pulmonary surfactant. Amsterdam: Elsevier, 1984:1–15.

Fujiwara T. Surfactant replacement in neonatal respiratory distress syndrome. In: Robertson B , Van Golde LMG , Batenburg JJ , eds. Pulmonary surfactant. Amsterdam: Elsevier, 1984:479–503.

Whitsett JA . Structure and function of pulmonary surfactant protein SP-A. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:9–17.

Phelps DS . Low-molecular-weight surfactant proteins. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:17–23.

Hawgood S. Surfactant-protein interactions. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus, OH: Ross Laboratories, 1988:24–30.

Hawgood S , Benson BJ , Schilling J , Damm D , Clements JA , White RT . Nucleotide and amino acid sequences of pulmonary surfactant protein SP 18 and evidence for cooperation between SP 18 and SP 28-36 in surfactant lipid absorption. Proc Natl Acad Sci USA 1987;84:66–70.

Fujiwara T , Maeta H , Chida S , Morita T , Watabe Y , Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;1:55–59.

Gitlin JD , Soll RF , Parad RB , . Randomized controlled trial of exogenous surfactant for the treatment of hyaline membrane disease. Pediatrics 1987;79:31–37.

Raju TN , Vidyasagar D , Bhat R , . Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. Lancet 1987;1:651–656.

Enhorning G , Shennan A , Possmayer F , Dunn M , Chen CP , Milligan J. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: A randomized clinical trial. Pediatrics 1985;76:145–153.

Kwong MS , Egan EA , Notter RH , Shapiro DL . Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 1985;76:585–592.

Shapiro DL , Notter RH , Morin FC III , . Double-blind randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 1985;76:593–599.

Hallman M , Merritt TA , Schneider H , . Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 1983;71:473–492.

Merritt TA , Hallman M , Bloom BT , . Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 1986;315:785–790.

Shapiro DL . Comments on dosage and timing of surfactant administration. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:117–121.

Clyman RI , Jobe A , Heymann M , . Increased shunt through the patent ductus arteriosus after surfactant replacement therapy. J Pediatr 1982;100:101–107.

Heldt GP , Merritt TA , Pesonen E , Hallman M , Sahn D. Surfactant therapy does not adversely influence closure of the patent ductus arteriosus. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:91–96.

Robertson BA . Surfactant and lung injury. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:62–67.

Lachmann B. Surfactant treatment for lung diseases other than the respiratory distress syndrome. In: Jobe AH , Taeusch HW , eds. Surfactant treatment of lung diseases: Report of the 96th Ross conference on pediatric research. Columbus OH: Ross Laboratories, 1988:123–128.

Macklem PT , Proctor DF , Hogg JC . The stability of peripheral airways. Respir Physiol 1970;8:191–203.